Frequencies of CD33+CD11b+HLA-DR–CD14–CD66b+ and CD33+CD11b+HLA-DR–CD14+CD66b– Cells in Peripheral Blood As Severity Immune Biomarkers in COVID-19

Ricardo Wesley Alberca,Milena Mary de Souza Andrade,Anna Claudia Calvielli Castelo Branco,Anna Julia Pietrobon,Natalli Zanete Pereira,Iara Grigoletto Fernandes,Luana de Mendonca Oliveira,Franciane Mouradian Emidio Teixeira,Danielle Rosa Beserra,Emily Araujo de Oliveira,Sarah Cristina Gozzi-Silva,Yasmim Alefe Leuzzi Ramos,Cyro Alves de Brito,Marcelo Arnone,Raquel Leao Orfali,Valeria Aoki,Alberto Jose da Silva Duarte,Maria Notomi Sato

Frontiers in medicine（2020）

引用 13|浏览66

暂无评分

摘要

Common clinical features of patients with Coronavirus disease-2019 (COVID-19) vary from fever, to acute severe respiratory distress syndrome. Several laboratory parameters are reported as indicators of COVID-19 severity. We hereby describe the possible novel severity biomarkers for COVID-19, CD11b+CD33+HLA-DR-CD14+ cells and CD11b+CD33+HLA-DR-CD66b+ cells.

查看译文

关键词

SARS-CoV-2,infection,COVID-19,biomarker,severity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要